Longwood Fund Announces Longwood Healthcare Leaders, a Virtual Meeting for Industry Leaders on Oct. 4-5, 2021

Longwood Fund, an early-stage life science venture firm focused on company creation, will convene several hundred top biotech and pharmaceutical leaders at its fall Longwood Healthcare Leaders meeting, hosted virtually via webconference, on October 4-5, 2021.  The meeting focuses on a broad spectrum of topics affecting the biopharma ecosystem. Biopharma CEOs and C-suite executives, heads of research and development, therapeutic area heads, top academic researchers, and healthcare investors will join off-the-record discussions of ideas, strategies and insights intended to help the community translate groundbreaking discoveries into medicines to help patients.
Hosted by Longwood Fund, senior industry leaders will speak in moderated keynotes, fireside chats, and discussion panels: Acting Commissioner of the U.S. Food and Drug Administration (FDA) Janet Woodcock; Massachusetts Governor Charlie Baker; Roche Pharmaceuticals CEO Bill Anderson; GlaxoSmithKline CSO and President of R&D Hal Barron; Janssen Pharmaceuticals Company Group Chairman, Global Commercial Strategy Organization Vanessa Broadhurst; Thermo Fisher Scientific Chair, President and CEO Marc Casper; Pfizer CSO and President of Worldwide Research, Development, and Medical Mikael Dolsten; AbbVie EVP and Chief Strategy Officer Henry Gosebruch; Moderna/Momenta co-founder Bob Langer; IPSEN CEO David Loew; Janssen Pharmaceuticals Global Head of R&D Mathai Mammen; Bayer Pharmaceuticals CEO Stefan Oelrich; Gilead EVP and CMO Merdad Parsey; Amgen EVP, R&D David Reese; Sanofi EVP and Global Head of R&D John Reed; Biogen EVP, R&D Al Sandrock; Vir Bio CEO and Director George Scangos; Nobel laureate and Biogen/Alnylam co-founder Phil Sharp; Takeda President and CEO Christophe Weber; Regeneron President and CSO George Yancopoulos, among others.
Topics discussed include collaboration and acceleration of research and development, launching and building biotech companies, expediting research for treatments and cures, sourcing and identifying novel technology, global drug development, innovation in cell therapy, board development, clinical trial efficiency, raising and managing capital, among many others.
Profits from the meeting benefit charities including Life Science Cares, The Boston Foundation, Boston Symphony Orchestra, Harvard Medical School, MIT, and others.  To learn more about the event, view the agenda, and request an invitation, visit www.longwoodhealthcareleaders.com.
Longwood Healthcare Leaders
Longwood Healthcare Leaders meetings are invitation-only forums typically held at leading academic institutions. Biopharma CEOs, heads of R&D, academic researchers, and healthcare investors join off-the-record discussions that generate new company ideas and approaches for Longwood Fund and members of the biopharma ecosystem, creating strategic business opportunities to advance the industry and bring important medicines to patients in need.
Longwood Fund
Longwood Fund is a venture capital firm dedicated to creating and investing in novel healthcare companies that develop important treatments to help patients while targeting significant value for investors.  The Longwood team has a long history of successfully launching and building important life science companies while providing operational leadership and strategic guidance.  Collectively, the Partners at Longwood Fund have co-founded 23 companies with over 20 launched or marketed drugs and therapies, as well as over two dozen clinical-stage assets, all focused on helping patients in need.  Companies founded by Longwood Fund, or its principals prior to the founding of the Firm, as lead investor and CEO/CBO include Vertex, Acceleron, Momenta, Alnylam, Sirtris, Vor, TScan, Pyxis Oncology, Immunitas, Be Biopharma, ImmuneID, and Tome Bio.  For more information, visit www.longwoodfund.com.
###
Source: Longwood Fund